CLINICAL-STUDY OF RECOVERY AND HALF-LIFE OF VAPOR-HEATED FACTOR-VII CONCENTRATE

被引：12
作者：
RIVARD, GE
KOVAC, I
KUNSCHAK, M
THONE, P
COHEN, LJ
EYSTER, ME
GRIBBLE, TJ
HATHAWAY, WE
KASPER, CK
NEUBERG, R
RUSTAGI, P
SMITH, K
机构：
[1] IMMUNO AG WIEN,CLIN TRIALS,A-1220 VIENNA,AUSTRIA
[2] UNIV MONTREAL,HOP ST JUSTINE,SERV HEMATOL,MONTREAL H3T 1C5,PQ,CANADA
来源：
TRANSFUSION | 1994年 / 34卷 / 11期
关键词：
D O I：
10.1046/j.1537-2995.1994.341195065036.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background: The in vivo recovery and half-life of intermediate-purity, vapor-heated factor VII (FVII) concentrate were determined in patients having a congenital deficiency for FVII according to the 1991 guidelines of the International Society for Thrombosis and Haemostasis. Study Design and Methods: A total of 11 patients received a single infusion of the FVII concentrate. Blood was drawn before infusion and 15 and 30 minutes and 1,2, 4, 8, 12, and 24 hours after. Recoveries were calculated from the highest FVII activity of the first four blood samples drawn after infusion. The two-phase linear regres- sion method was used to estimate the half-life according to the two-compartment model. In addition, a noncompartmental approach was applied. Results: The mean recovery value obtained for FVII concentrate, 110.53 percent (SD, +/- 26.37), indicates rapid and efficient incorporation into the blood stream. Equivalent results were obtained with both pharmacokinetics methods and indicate a very short half-life for FVII. A half-life of 6.49 hours (SD, +/- 2.42) with the compartmental method and a half-life of 5.25 hours noncompartmental method. Conclusion: The half-life and recovery reported here, along with the specificity of the replacement therapy, the earlier anecdotal cases of clinical efficacy, and the clinical safety of the concentrate with regard to viral infections, recommend vapor-heated FVII concentrate for the treatment of patients with hereditary FVII deficiency.
引用
收藏
页码：975 / 979
页数：5
相关论文
共 50 条
[31]   Extended half-life clotting factor concentrates: results from published clinical trials [J].
Young, G. ;
Mahlangu, J. N. .
HAEMOPHILIA, 2016, 22 :25-30
[32]   CLINICAL APPLICATION OF EXTENDED HALF-LIFE FACTOR VIII AND IX IN CHILDREN WITH HAEMOPHILIA A AND B [J].
Dettoraki, A. ;
Michalopoulou, A. ;
Saslis, S. ;
Kapsimali, Z. ;
Mazarakis, M. ;
Thymianou, S. ;
Stamati, I. ;
Pergantou, H. .
HAEMOPHILIA, 2021, 27 :53-54
[33]   HEPARIN SMALL POOL HIGH-YIELD PURIFIED FACTOR-VIII - INVIVO RECOVERY AND HALF-LIFE OF ROUTINELY PRODUCED FREEZE-DRIED CONCENTRATE [J].
SIBINGA, CTS ;
DAENEN, SMGJ ;
VANIMHOFF, GW ;
MAAS, A ;
DAS, PC .
THROMBOSIS AND HAEMOSTASIS, 1984, 51 (01) :12-15
[34]   Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products [J].
Eduardo Megias, Juan ;
Bonanad Boix, Santiago ;
Martinez Garcia, Maria Fernanda ;
Berrueco, Ruben ;
Eva Mingot-Castellano, Maria ;
Rodriguez Lopez, Manuel ;
Canaro, Mariana ;
Mateo Arranz, Jose ;
Larrode Lecinena, Itziar ;
Haya, Saturnino ;
Santamaria Ortiz, Amparo ;
Albo, Carmen ;
Mesegue Medea, Montserrat ;
Palomero-Massanet, Antonio ;
Vilalta Seto, Noelia ;
Calvo Villas, Jose Manuel ;
Cid, Ana R. ;
Robayo, Gustavo ;
Poveda Andres, Jose Luis ;
Sanz, Guillermo F. ;
Iorio, Alfonso .
BLOOD, 2019, 134
[35]   Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect [J].
Mathijssen, Natascha C. J. ;
Masereeuw, Rosalinde ;
Holme, Pal Andre ;
van Kraaij, Marian G. J. ;
Laros-van Gorkom, Britta A. P. ;
Peyvandi, Flora ;
van Heerde, Waander L. .
THROMBOSIS RESEARCH, 2013, 132 (02) :256-262
[36]   COMPARISON OF RECOVERY AND HALF-LIFE OF A NEW FACTOR-VIII HIGH-PURITY CONCENTRATE (FVIII-C-HS) WITH A FACTOR-VIII-HS (HEMATE-P) [J].
SCHIMPF, K ;
REIS, B .
RICERCA IN CLINICA E IN LABORATORIO, 1986, 16 (01) :231-231
[37]   PLASMA FACTOR-VII, TRIGLYCERIDE CONCENTRATION AND FIBRIN DEGRADATION PRODUCTS IN PRIMARY HYPERLIPIDEMIA - A CLINICAL AND LABORATORY STUDY [J].
DESOUSA, JC ;
BRUCKERT, E ;
GIRAL, P ;
SORIA, C ;
TRUFFERT, J ;
MIRSHAHI, MC ;
DEGENNES, JL ;
CAEN, JP .
HAEMOSTASIS, 1989, 19 (02) :83-90
[38]   INVIVO RECOVERY, HALF-LIFE, SAFETY, AND HEMOSTATIC EFFICACY OF AFFINITY-PURIFIED FACTOR-VIII [J].
GOLDSMITH, JC ;
KASPER, CK ;
ABRAMSON, SB ;
BATTACHARYA, P ;
NOVAK, P .
TRANSFUSION, 1992, 32 (05) :488-488
[39]   The FIX C assessment of extended half-life recombinant factor IX products in clinical practice [J].
Bowyer, A. ;
Sampson, B. ;
Shepherd, F. ;
Jones, R. ;
Kitchen, S. ;
Makris, M. .
HAEMOPHILIA, 2018, 24 :56-56
[40]   HEMOPHILIC PATIENTS WITH AN INHIBITOR TO FACTOR-VIII TREATED WITH HIGH-DOSE FACTOR-VIII CONCENTRATE - RESULTS OF A COLLABORATIVE STUDY FOR THE EVALUATION OF FACTOR-VIII INHIBITOR TITER, RECOVERY AND HALF-LIFE OF INFUSED FACTOR-VIII [J].
SULTAN, Y ;
WHITE, GC ;
ARONSTAM, A ;
BOSSER, C ;
BRACKMANN, HH ;
BROCHIER, G ;
GORMSEN, J ;
MARIANI, G ;
ROBERTS, HR ;
SCARABIN, Y ;
SCHARRER, I ;
SCHEIBEL, E .
NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1986, 28 (02) :85-89
12345